Skip to main navigation
  • Follow Us:
  • Grant Portal
Catalystpharma.com

Corporate Menu

  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • News & Events
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
      • MuSK-MG Clinical
      • SMA Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page
Investors

Mobile Menu

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Investors

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Events & Presentations

Jun 8, 2022 at 11:00 AM EDT
Jefferies Healthcare Conference
May 24, 2022 at 4:00 AM EDT
HCW Wainwright conference
More

Latest Press Releases

May 17, 2022
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 10, 2022
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
More

Stock Quote

Change
Volume
52 Week High
52 Week Low
Jul 3, 2022 1:39 PM EDT
More
Best Companies

Toolkit

  • Email Alerts

  • RSS

  • Print page

  • Search

Footer Menu

  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • NEWS & EVENTS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us


FOLLOW US:
facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement